US 11491212
Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
granted A61KA61K38/4846A61K9/0019
Quick answer
US patent 11491212 (Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B) held by Catalyst Biosciences, Inc. expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Catalyst Biosciences, Inc.
- Grant date
- Tue Nov 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 27
- CPC classes
- A61K, A61K38/4846, A61K9/0019, A61P, A61P7/04